ÂÜÀòÂÒÂ×

Eda Canales has over 15 years of experience in pharmaceutical research and leadership, currently serving as Director at Gilead Sciences since June 2008, overseeing project teams and leading initiatives in drug development. Previously held roles include Principal Scientist focusing on inflammation and leading the GS-5290 Global Development Team as well as being a co-inventor of significant compounds like GS-5290, a TPL2 inhibitor for inflammatory bowel disease, and Lenacapavir (GS-6207), a long-acting HIV capsid inhibitor. Eda Canales has also contributed to the development of GS-9669, an NS5B site II inhibitor during earlier stages of their career. Educational background includes a Ph.D. in Chemistry from Harvard University and graduate studies at the University of Puerto Rico.